AstraZeneca Unit Hits Back At Samsung In Soliris Patent Duel
Alexion has struck back at Samsung Bioepis as the pair continue their Soliris patent quarrel, and has told a court that its formula for a drug that treats rare blood diseases is...To view the full article, register now.
Already a subscriber? Click here to view full article